S-1/A: Cosmos Health Inc. Faces Going Concern Doubts Amidst Nasdaq Compliance Challenges and New Capital Raise Efforts

Cosmos Health Inc. is seeking to raise up to $7.5 million through a new offering of common stock and warrants to address its significant operating losses and substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq minimum bid price non-compliance notice.

Summary

• Cosmos Health Inc. is a diversified, vertically integrated global healthcare group involved in proprietary pharmaceutical and nutraceutical brands, generics, manufacturing, distribution, R&D, and telehealth.
• The company is offering up to 10,714,286 shares of common stock, 10,714,286 pre-funded warrants, and 10,714,286 common warrants at an assumed purchase price of $0.70 per share, with an estimated net proceeds of approximately $6.9 million from the maximum offering.
• For the three months ended March 31, 2025, the company reported revenue of $13,712,528 and a net loss of $818,097, a significant improvement from a net loss of $1,866,690 in the prior-year period.
• For the year ended December 31, 2024, Cosmos Health reported revenue of $54,426,402 and a net loss of $16,183,018, compared to a net loss of $18,542,654 on revenue of $53,376,874 for 2023.
• As of March 31, 2025, the company had positive working capital of $1,259,012, an accumulated deficit of $114,840,372, and stockholders' equity of $25,951,712.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months, citing that current revenues cannot sustain operations and concerns about meeting obligations.
• The company received a Nasdaq non-compliance letter on November 6, 2024, for failing to meet the minimum bid price requirement of $1.00, and was granted an extension until November 3, 2025, to regain compliance.
• Proceeds from the offering are intended to support the acquisition of cryptocurrencies for a digital asset treasury strategy, for working capital purposes, and potentially to repay outstanding convertible notes.
• The company's R&D efforts include novel medicines for CNS cancer, prostate, ovarian, and colorectal cancers, and an obesity/weight management pill (CCX0722) targeting a Q1/Q2 2026 market launch.
• Recent acquisitions include ZipDoctor Inc. (telehealth), Cana Laboratories (pharmaceutical manufacturing), Bikas (pharmaceutical distribution network), and Cloudscreen (AI-powered drug repurposing platform).

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a 'going concern' warning from management and auditors, significant accumulated losses, and Nasdaq delisting risk. While there are strategic growth initiatives and R&D in promising areas, the immediate financial instability and reliance on future capital raises for survival overshadow these positives, indicating a highly precarious situation for investors.

Positives

• Net loss significantly decreased by approximately $1,048,593 for the three months ended March 31, 2025, compared to the same period in 2024, primarily due to improved gross profit from higher-margin product lines.
• Gross profit increased by 53.7% to $2,049,799 for the three months ended March 31, 2025, driven by a favorable shift towards higher-margin nutraceutical products and a reduction in Cost of Goods Sold.
• Operating expenses decreased by 9.05% to $2,882,944 for the three months ended March 31, 2025, reflecting cost containment initiatives, particularly in personnel and sales/marketing expenses.
• Net cash used in operating activities significantly improved, decreasing from $3,412,103 in Q1 2024 to $186,316 in Q1 2025.
• The company achieved positive working capital of $1,259,012 as of March 31, 2025, an improvement from negative working capital of $296,193 as of December 31, 2024.
• Revenue for the full year ended December 31, 2024, increased by 1.97% to $54,426,402, driven by wholesale revenue growth and the full-year inclusion of the CANA manufacturing subsidiary.
• Net operating loss for the 12 months ended December 31, 2024, improved by $6,286,387 (28.8%) compared to the prior year, primarily due to lower provisions for expected credit losses and reduced sales and marketing expenses.
• The company has an exclusive distribution agreement with Pharmalink for its Sky Premium Life products in the UAE, with anticipated orders of over 500,000 units in the first year and over 3,000,000 units over five years.
• Strategic acquisitions, including Cana Laboratories (GMP license for EU manufacturing) and Cloudscreen (AI-driven drug repurposing platform), have strengthened core product technology and R&D capabilities.
• The company has filed patent applications for repurposed drugs targeting multiple sclerosis, gliomas, and hematologic malignancies, with promising preclinical discoveries and in vitro studies.
• The CCX0722 obesity and weight management pill is finalizing its scale-up production phase, with human clinical trials set to complete between end of 2025 and beginning of 2026, targeting a Q1/Q2 2026 market launch.

Negatives

• The company has a history of significant losses, with an accumulated deficit of $114,840,372 as of March 31, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months, as current revenues are not able to sustain operations.
• The company received a Nasdaq non-compliance notice on November 6, 2024, for failing to meet the minimum bid price requirement of $1.00, and despite an extension until November 3, 2025, delisting remains a risk.
• The proposed offering is on a 'reasonable best efforts basis' with no minimum amount required, meaning the company may not raise sufficient capital to fund its business plans.
• The company will need to raise additional funding beyond this offering to fund operations and potential future acquisitions, and there is no assurance that such financing will be available on acceptable terms or at all.
• Revenue for the three months ended March 31, 2025, decreased by 5.98% compared to the same period in 2024, predominantly due to unfavorable foreign exchange movements (Euro depreciation) and a marginal decrease in wholesale sales.
• Interest income decreased by 13.65% for the three months ended March 31, 2025, due to loan repayments reducing outstanding loan receivable balances.
• The company recognized impairment charges of $291,980 for the year ended December 31, 2024, related to certain branded pharmaceutical products and the telehealth platform (Zip Doctor Inc.) due to changes in commercialization strategy and discontinuation of operations.
• The investment in CosmoFarmacy LP was fully impaired during the 12-month period ended December 31, 2024, as the entity is dormant and has not provided financial statements to substantiate its carrying value.
• The company's stock price has been and may continue to be volatile, and its shares are thinly traded, which may not reflect its true value and could limit liquidity.
• The potential use of offering proceeds to invest in digital assets (cryptocurrencies) introduces numerous additional risks, including technological, operational, financial, regulatory, and reputational risks, with no assurance of return.

Risks

• Resales of common stock by shareholders after the offering may cause the market price to fall due to potential ownership dilution.
• The offering may cause the trading price of common stock to decrease due to the price per share and number of shares issued.
• Investors will experience immediate and substantial dilution in net tangible book value per share.
• Future equity offerings could result in further dilution and downward pressure on the stock price.
• Management has broad discretion over the use of net proceeds, including potential investment in cryptocurrencies, which may not align with investor expectations or yield favorable returns.
• The 'reasonable best efforts' nature of the offering means the company may not raise the required capital for its business plans.
• Failure to obtain additional capital may force the company to limit or terminate operations.
• The company's stock price may be volatile due to various factors including industry changes, competition, capital needs, and regulatory developments.
• Thinly traded common stock may not reflect the company's value, and there is no assurance of an active market.
• Offers or availability for sale of a substantial number of shares could cause the stock price to decline (overhang risk).
• There is no public market for the Pre-Funded Warrants or Common Warrants, limiting their liquidity.
• Holders of warrants have no rights as common stock holders until exercise.
• Pre-Funded Warrants are speculative in nature, and their market value may not equal or exceed their public offering price.
• Common Warrants may not have any value if the market price of common stock does not exceed their exercise price.
• Provisions of the Common Warrants could discourage third-party acquisitions.
• Investment in digital assets exposes the company to technological, operational, financial, regulatory, and reputational risks, with no assurance of generating return.
• The company has a history of significant losses and risks losing the entire investment.
• The company's financial statements are prepared assuming it will continue as a going concern, but substantial doubt exists.
• The company has an evolving operating history with substantial losses and no guarantee of continued profitability.
• Revenues are concentrated in specific markets, making the company vulnerable to market downturns.
• Loss of the Chief Executive Officer, Grigorios Siokas, could disrupt operations.
• The company lacks sufficient financial resources to successfully complete product development, marketing, and certain acquisitions.
• Drug development programs require substantial additional capital, and funding may not be available on acceptable terms.
• Inability to attract and retain key scientific and management personnel could harm the business.
• The company is subject to rigorous and evolving regulations in the EU, UK, and Greece, with risks of non-compliance, fines, and product withdrawals.
• Future acquisitions could disrupt business, cause dilution, and introduce unforeseen costs or liabilities.
• Exposure to potential product liability claims, with no guarantee of adequate insurance coverage.
• Discovery of safety issues with products could lead to product liability, regulatory scrutiny, and penalties.
• The company is subject to anti-corruption laws, and non-compliance could result in substantial penalties.
• Difficulty in obtaining regulatory approval for new products or developing new products.
• Significant competition from larger and better-funded enterprises in the pharmaceutical and nutraceutical markets.
• Concentration risk in relation to suppliers and production, leading to potential supply chain disruptions.
• Negative market perceptions of the company, its brands, or product safety could adversely affect the business.
• International risks, including differing local preferences, trade protection measures, political/economic instability, and currency fluctuations.
• Impact of international economic conditions, including sovereign debt issues and currency devaluations.
• Market disruptions, supply-chain disruptions, geopolitical conflicts (e.g., war in Ukraine), macroeconomic events, and inflation could negatively impact business.
• Currency risks related to conversion to Euros and GBP.
• Inability to defend or protect intellectual property, relying on trade secrets and know-how.
• Risk of being sued by third parties for intellectual property infringement or wrongful use of trade secrets.
• Governmental and third-party payors may impose pricing restrictions, limiting future product revenues.
• Commercial success depends on market acceptance by physicians, patients, and the medical community.
• Risks related to critical accounting policies and potential incorrect interpretation or implementation.
• Failure to remediate material weaknesses in internal controls could lead to SEC deregistration and Nasdaq delisting.
• Nevada anti-takeover law may discourage acquirers.
• No anticipated cash dividends; shareholders must rely on stock appreciation.
• Board's power to issue preferred stock may act as an anti-takeover device and dilute common stock.
• Public company compliance requires significant resources and management attention, diverting from business operations.
• Future sales or dilution of equity may adversely affect the market price of common stock.
• Lack of research or adverse changes in recommendations by securities analysts could cause stock price decline.
• Forward-looking statements are speculative and uncertain, and actual results may differ materially.

Future Outlook

Management believes that net proceeds of $3,750,000 from this offering, combined with cash on hand, will satisfy capital needs for six months, and $7,500,000 will satisfy capital needs for 12 months under the current business plan. The company plans to raise additional capital through equity or debt financings, expand brand name products, broaden its product portfolio, and evaluate acquisition targets to expand distribution. It also intends to vertically integrate its supply chain, utilize an S-3 registration statement from August 2025 for more efficient equity capital raising, and potentially postpone certain debt repayments and supplier/creditor payments. The company anticipates its significant operating investments will yield positive results and improve cash flows in the near term.

Management Comments

• "It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing."
• "The Company's revenues are not able to sustain its operations, and concerns exist regarding the Company's ability to meet its obligations as they become due."
• "Even though there is no assurance, we believe that we will be able to regain compliance with Nasdaq's minimum bid-price requirement for continued listing through appreciation of our securities."
• "Management is confident that the Company's current liquidity position, along with its ongoing financing and investment strategies, will enable it to meet its financial obligations and continue its growth trajectory in the coming periods."
• "We are committed to serving our customers while continuing to innovate and provide products that make a difference in the lives of individuals. We strive to maximize our shareholders value by adapting to market realities and customer needs."
• "We are committed to driving organic growth at attractive margins by improving execution, optimizing cash flow and leveraging our strong market position, while maintaining a streamlined cost structure throughout each of our businesses."
• "We anticipate that these significant operating investments should yield positive results soon, contributing to future operating profits and positive operating cash flows."

Industry Context

Cosmos Health operates within the growing global healthcare sector, specifically targeting the generic drugs, nutraceuticals, obesity & weight management, hospital disinfectant, oncology drugs, and drug repurposing markets. These markets are projected to experience significant Compound Annual Growth Rates (CAGRs) ranging from 2.9% to 11.3% over the next decade, driven by factors such as patent expirations, increasing demand for cost-effective medicines, and a shift towards preventive health. The company's strategy of vertical integration, R&D in innovative treatments (e.g., AI-driven drug repurposing, novel oncology drugs), and expansion into new geographical regions (e.g., UAE) aligns with these broader industry trends, aiming to capitalize on high-growth segments and enhance market share.

Comparison to Industry Standards

• The global generic drugs market was valued at $424.98 billion in 2024 and is projected to reach $874.63 billion by 2033, representing a CAGR of 8.35%. Cosmos Health's focus on generic medicines aligns with this growth trend.
• The global nutraceuticals market size is calculated at USD 591.15 billion in 2024 and is projected to reach around USD 1,234 billion by 2034, expanding at a CAGR of 7.64%. Cosmos Health's proprietary brands like Sky Premium Life and Mediterranation position it within this expanding market.
• The global obesity & weight management market is expected to be worth USD 362.1 billion by 2034, expanding at a CAGR of 8.3%. Cosmos Health's R&D into CCX0722 for obesity and weight management targets a significant and growing health concern.
• The global oncology drugs market size was valued at USD 201.75 billion in 2023 and is projected to grow to USD 518.25 billion by 2032, exhibiting a CAGR of 11.3%. Cosmos Health's acquisition of Cloudscreen (AI drug repurposing) and its R&D into novel anticancer drugs for CNS, prostate, ovarian, and colorectal cancers align with this high-growth segment.
• The global drug repurposing market is anticipated to reach USD 30.1 billion by 2028, reflecting a CAGR of 2.9%. Cosmos Health's Cloudscreen platform and patent filings in this area demonstrate its participation in a key strategic approach for pharmaceutical companies.
• The company's acquisition of Cana Laboratories, a Greek pharmaceutical company with a Good Manufacturing Practice (GMP) license, allows it to engage in contract manufacturing (CMO/CDMO), a common practice among major multinational pharmaceutical companies to optimize production and leverage assets.

Management Changes

Corporate Governance

Legal Proceedings

• A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014, which Cosmofarm appealed but was dismissed. The company settled $99,644 but has filed a claim to recover the amount.
• A criminal case involving dishonored checks issued by Cosmofarm's customer, Filippou, resulted in the defendant being found guilty on November 27, 2023.
• A criminal case involving dishonored checks issued by Cosmofarm's customer, Kafantaris, resulted in the defendant being convicted on January 26, 2024.
• The company's appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 was partially accepted, with the case settled in two equal installments by Cosmofarm SA totaling approximately $75,873.
• Cana Laboratories has two pending lawsuits against Euaggelismos Hospital for unpaid bills totaling 526,436 EUR, with one court date scheduled for December 11, 2024, and the other unscheduled. Collection of the full amount is considered highly probable.
• An unasserted claim exists against Papanikolaou Hospital for 89,300 EUR due to unpaid bills, which will be asserted through a lawsuit, with collection considered probable.
• A lawsuit has been filed against Cana Laboratories seeking restitution of a leased property, with monetary claims of approximately 13,190 EUR in outstanding rent and 8,488 EUR in compensation for use of the property settled, but the claim for property restitution remains pending.
• Cosmofarm SA is initiating legal action to recover approximately 20,301 EUR in unpaid invoices from a customer, with the hearing expected in 2026.
• Cosmofarm SA is preparing to file two further lawsuits for the recovery of 15,143 EUR and 15,255 EUR, respectively, related to unpaid invoices concerning two customers, with hearings expected in 2026 and favorable outcomes anticipated.

Related Party Transactions

• Grigorios Siokas (CEO and principal shareholder) has historically loaned the company non-interest bearing, no-term funds. As of March 31, 2025, the outstanding principal balance was $0, down from $6,194 as of December 31, 2024. Between January 13, 2025, and March 4, 2025, the company issued 1,053,372 shares of common stock to Mr. Siokas in settlement of $649,000 in outstanding obligations (unpaid salaries and bonuses).
• Dimitrios Goulielmos (former CEO and Director) has a non-interest bearing, no-maturity loan with the company, with a principal balance of $11,012 as of March 31, 2025.
• Doc Pharma S.A. (related party, CEO's son is Doc Pharma CEO) has significant ongoing transactions: prepaid balances of $3,549,574 (March 31, 2025) for inventory purchases, licenses, and royalty agreements; accounts payable of $345,702 (March 31, 2025); and accounts receivable of $2,469,234 (March 31, 2025), with a cumulative allowance for doubtful accounts of approximately $1.4 million. The company purchased $300,208 of products from Doc Pharma and sold $130,362 to Doc Pharma during Q1 2025. A royalty-bearing, exclusive worldwide license agreement for cancer patents was signed on December 31, 2024, with initial payment of 500,000 EUR and annual payments of 350,000 EUR.
• Panagiotis Kozaris (former General Operational Manager and current employee of Cosmofarm S.A.) has prepaid balances of $194,215 (March 31, 2025) for shares the company intends to purchase back.
• Basotho Investment Limited (related to Panagiotis Kozaris) received 120,000 shares of common stock for services rendered on November 21, 2023, and an additional 440,000 shares on September 17, 2024, as complementary compensation.
• Maria Kozari (daughter of Panagiotis Kozaris) owns Pharmacy & More, a customer of Cosmofarm SA. Net sales to Pharmacy & More were $100,870 in Q1 2025, with an outstanding receivable balance of $1,188,908 (March 31, 2025) and a cumulative allowance for doubtful accounts of $773,051. The company plans to acquire Pharmacy & More in fiscal year 2025.
• Unpaid salaries and bonuses are owed to Grigorios Siokas ($76,865), George Terzis ($168,000), and Nikolaos Bardakis ($15,000) as of March 31, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the current offering and potential future equity raises. Risk of substantial loss of investment due to ongoing losses, going concern doubts, and potential Nasdaq delisting. The stock price is volatile and thinly traded. Existing warrant holders may experience further dilution upon exercise of new warrants.
• **Employees**: The company is focused on hiring and retaining a highly skilled management team and plans to increase the number of salespeople, indicating potential growth opportunities. However, cost containment initiatives have led to reductions in personnel expenses, which could impact job security or compensation for some.
• **Customers**: The company aims to expand its distribution network and product portfolio, potentially offering a broader range of pharmaceutical and nutraceutical products. Investments in automated distribution facilities (ROWA robotics) aim to improve service quality and efficiency.
• **Suppliers**: The company's business depends on timely supply of materials and services. Management is considering postponing certain repayments to suppliers, which could strain relationships.
• **Creditors**: The company is seeking to postpone certain debt repayments and obtain additional debt financing, indicating potential challenges in meeting obligations. The going concern warning raises concerns about the recoverability of loans.
• **Regulatory Authorities**: The company is subject to rigorous regulations and compliance requirements, with risks of fines and product withdrawals for non-compliance. Nasdaq's non-compliance notice highlights regulatory scrutiny.

Next Steps

• Complete the current offering of common stock and warrants to raise capital.
• Implement the digital asset treasury strategy, including the acquisition of cryptocurrencies.
• Continue efforts to regain compliance with Nasdaq's minimum bid price requirement by November 3, 2025, potentially through a reverse stock split.
• Finalize the scale-up production phase of CCX0722 (obesity & weight management pill) and engage with CROs for human clinical trials, targeting completion by end of 2025/early 2026 for a Q1/Q2 2026 market launch.
• Advance Clinical Phase I trials for the two patented anticancer drugs targeting prostate, ovarian, and colorectal cancers.
• Continue R&D efforts on IP-driven products like CCDL24 and further leverage the Cloudscreen AI-driven drug repurposing platform.
• Expand and consolidate sales distribution networks of proprietary brands through strategic agreements in new regions (e.g., UAE, GCC countries, Eastern Europe).
• Continue corporate reorganization to streamline costs and enhance asset/resource utilization through business unit integration and cost optimization initiatives.
• Improve collections and reduce allowances for doubtful accounts to positively impact working capital and liquidity.
• Pursue additional debt financing and favorable amendments to existing debt facilities.
• Consider postponing certain repayments of suppliers and creditors.
• Acquire Pharmacy & More within fiscal year 2025 and make it the first shop-in-shop for Sky Premium Life products.
• Utilize S-3 registration statement from August 2025 to raise equity capital more efficiently.
• Continue to hire and retain highly skilled management, scientific, and sales personnel.

Key Dates

Recommendation

Keywords

Pharmaceuticals, Nutraceuticals, Healthcare, Generics, Drug Repurposing, Telehealth, Biocides, Medical Devices, Oncology Drugs, Nasdaq Listing, S-1/A Filing, Public Offering, Warrants, Going Concern, Capital Raise, R&D, Supply Chain, International Operations, Corporate Governance, Risk Management